99% Purity CAS No.: 128270-50-0 Powder Peptide Bivalirudin Trifluoroacetate

Appearence: White Powder
Supply Ability: 500000kg/Year
Certificate: GMP
Packing: Plastic Tube
Shelf Life: 2years
Storage Way: Dry and Cool Place
Trademark: FILTER
Transport Package: Plastic Tube / Vial
Specification: 2mg/vial, 10vials/box
Origin: Shanghai
HS Code: 3003901000
Appearence: White Powder
Supply Ability: 500000kg/Year
Certificate: GMP
Packing: Plastic Tube
Shelf Life: 2years
Storage Way: Dry and Cool Place
Trademark: FILTER
Transport Package: Plastic Tube / Vial
Specification: 2mg/vial, 10vials/box
Origin: Shanghai
HS Code: 3003901000
99% Purity CAS No.: 128270-50-0 Powder Peptide Bivalirudin Trifluoroacetate

 Production Information:
Product Name: Bivalirudin Trifluoroacetate
Synonyms: BIVALIRUDIN;BIVALIRUDIN TRIFLUOROACETATE;Bivalirudin, TFA;BITTERMELONP.E;Human Bivalirudin;Bivalirudin Acetate;Bivalirudin BG 8967, Hirulog, Hirulog I;BG 8967, Hirulog, Hirulog I
CAS: 128270-60-0
MF: C98H138N24O33
MW: 2180.29
EINECS: --
Product Categories: Peptide;API;proteins
Purity: 99%,98%

Production Information:
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin.It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin. 
 

Application:
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

99% Purity CAS No.: 128270-50-0 Powder Peptide Bivalirudin Trifluoroacetate
 


Contact us:
Maria
 
 
 
 
99% Purity CAS No.: 128270-50-0 Powder Peptide Bivalirudin Trifluoroacetate

 Production Information:
Product Name: Bivalirudin Trifluoroacetate
Synonyms: BIVALIRUDIN;BIVALIRUDIN TRIFLUOROACETATE;Bivalirudin, TFA;BITTERMELONP.E;Human Bivalirudin;Bivalirudin Acetate;Bivalirudin BG 8967, Hirulog, Hirulog I;BG 8967, Hirulog, Hirulog I
CAS: 128270-60-0
MF: C98H138N24O33
MW: 2180.29
EINECS: --
Product Categories: Peptide;API;proteins
Purity: 99%,98%

Production Information:
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin.It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin. 
 

Application:
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

99% Purity CAS No.: 128270-50-0 Powder Peptide Bivalirudin Trifluoroacetate
 


Contact us:
Maria
 
 
 
 

3D Face Mask

FACE Mask 3D style

3D Face Mask,3D Face Mask Covid,3D Animal Face Mask,3D Face Mask Black

Zhejiang Lanhine Medical Products Ltd. , https://www.lanheyiliao.com

Posted on